We are live on ! Find out more
MG

Michael Gelband ExodusPoint Capital Management

AUM $15.5B
1-Year Est. Return 38.81%
 

Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.

This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+38.81%
3 Year Est. Return
+110.53%
5 Year Est. Return
+124.16%
10 Year Est. Return
AUM
$3.85B
AUM Growth
+$2.03B
Cap. Flow
+$1.66B
Cap. Flow %
43.05%
Top 10 Hldgs %
17.46%
Holding
2,172
New
1,142
Increased
418
Reduced
161
Closed
448

Sector Composition

Rank Sector Weight
1 Technology 15.36%
2 Healthcare 10.23%
3 Industrials 9.8%
4 Financials 9.25%
5 Consumer Discretionary 7.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FPRX
1276
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$330K 0.01%
+54,094
New +$223K
DNTH icon
1277
Dianthus Therapeutics
DNTH
$6.16B
$329K 0.01%
+2,736
New +$385K
GRMN
1278
Garmin
GRMN
$56.2B
$328K 0.01%
+3,364
New +$288K
CORR
1279
DELISTED
CorEnergy Infrastructure Trust, Inc.
CORR
$328K 0.01%
+35,826
New +$451K
DDS icon
1280
Dillards
DDS
$10B
$327K 0.01%
+12,687
New +$359K
IART icon
1281
Integra LifeSciences
IART
$1.3B
$324K 0.01%
+6,892
New +$339K
QVCGA
1282
DELISTED
QVC Group Inc Series A
QVCGA
$324K 0.01%
704
+60
+9% +$23.4K
CLH icon
1283
Clean Harbors
CLH
$16.6B
$323K 0.01%
+5,389
New +$300K
PANW icon
1284
Palo Alto Networks
PANW
$286B
$322K 0.01%
+8,406
New +$296K
RAD
1285
DELISTED
Rite Aid Corporation
RAD
$322K 0.01%
+18,884
New +$255K
ODT
1286
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$322K 0.01%
+7,600
New +$246K
NXRT
1287
NexPoint Residential Trust
NXRT
$631M
$321K 0.01%
+9,081
New +$281K
CBAY
1288
DELISTED
Cymabay Therapeutics
CBAY
$321K 0.01%
+91,992
New +$265K
EGHT icon
1289
PUT
8x8 Inc
EGHT
$286M
$320K 0.01%
+20,000
New +$318K
AZN icon
1290
AstraZeneca
AZN
$259B
$319K 0.01%
+3,019
New +$312K
CROX icon
1291
Crocs
CROX
$6.03B
$319K 0.01%
+8,662
New +$229K
OTTR icon
1292
Otter Tail
OTTR
$3.86B
$318K 0.01%
+8,209
New +$345K
INFN
1293
DELISTED
Infinera Corporation Common Stock
INFN
$317K 0.01%
+53,501
New +$293K
THBRU
1294
DELISTED
Thunder Bridge Acquisition II, Ltd. Units
THBRU
$315K 0.01%
+30,000
New +$313K
FSRVU
1295
DELISTED
FinServ Acquisition Corp. Unit, 1 Com, 1/2 Wt.
FSRVU
$315K 0.01%
+30,000
New +$309K
INMD icon
1296
InMode
INMD
$869M
$314K 0.01%
+22,208
New +$297K
SNPS icon
1297
Synopsys
SNPS
$75.5B
$314K 0.01%
1,612
-7,129
-82% -$1.18M
HCI icon
1298
HCI Group
HCI
$2.31B
$312K 0.01%
+6,760
New +$293K
KURA icon
1299
Kura Oncology
KURA
$1.1B
$312K 0.01%
+19,169
New +$277K
MGRC icon
1300
McGrath RentCorp
MGRC
$2.85B
$312K 0.01%
+5,784
New +$310K

Similar funds

Michael Gelband's Q2 2020 Portfolio in Review

As of Q2 2020, Michael Gelband held 2,172 positions worth $3.85B, up 111% from $1.82B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Michael Gelband deployed $1.66B of net new capital in Q2 2020, opening 1,142 new positions and adding to 418 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 266,338 shares worth $82.1M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 12% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Amazon, an estimated $27.8M trimmed.

  • Michael Gelband's largest Q2 2020 buy was State Street SPDR S&P 500 ETF Trust: 266,338 shares worth $82.1M.
  • Michael Gelband added most to PG&E in Q2 2020, an estimated $38.2M increase.
  • Michael Gelband's biggest Q2 2020 reduction was Amazon, cutting an estimated $27.8M.
  • Michael Gelband fully exited McKesson in Q2 2020, selling an estimated $18.1M.
  • Michael Gelband's ten largest holdings make up 17% of its $3.85B portfolio in Q2 2020.
  • Michael Gelband opened 1,142 new positions and closed 448 in Q2 2020.
  • Michael Gelband's portfolio value rose 111% quarter-over-quarter to $3.85B.

Based on ExodusPoint Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.